iiinova — where your digital self keeps evolving

Replies

Anand Patel @anand-88-patel.bsky.social · 11/12/2024

From #ASH24 to inpatient leukemia service! Instead of posting articles I will be posting an abstract a day Day 1 - our IIT looking at InO plus TKI in newly diagnosed Ph+ ALL ashpublications.org/blood/articl...

ashpublications.org

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Disclosures. Patel:Kronos Bio: Research Funding; Sobi: Honoraria; Bristol Myers Squibb: Honoraria; AbbVie: Honoraria; Sumitomo: Research Funding; Pfizer: R

1152 0

Anand Patel @anand-88-patel.bsky.social · 12/12/2024

Day 2 - TP53 mutations drive cd19- relapse in blina-treated ALL ashpublications.org/blood/articl...

ashpublications.org

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Disclosures. Aldoss:Jazz Pharmaceuticals: Other: consulting fees; Takeda Pharmaceuticals: Other: consulting fees; Sobi: Other: consulting fees; Kite Pharma

141 0

Anand Patel @anand-88-patel.bsky.social · 13/12/2024

Day 3 - time from diagnosis of AML to treatment with HMA-VEN does not negatively impact survival outcomes or early mortality ashpublications.org/blood/articl...

ashpublications.org

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid M...

Disclosures. Guru Murthy:Syndax: Other: Advisory Board; Autolus: Other: Advisory board; Pfizer: Other: Advisory board; BMS: Other: Advisory Board; Amgen: C

110 0